Transpara vs ScreenPoint Medical

Direct competitors — feature-level head-to-head below. Comparability 95/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Transpara

by ScreenPoint Medical

ScreenPoint Medical

by ScreenPoint Medical

AI Verdict

Tool A, "Transpara," is the specific AI-powered breast cancer detection solution offered by the company described in Tool B, "ScreenPoint Medical." Both descriptions refer to the same core product and its capabilities, with Tool B providing a broader company overview that encompasses the product detailed in Tool A. Therefore, they are essentially describing the same offering from different perspectives.

Choose Transpara if…

Choose Transpara if your primary goal is to enhance the efficiency and accuracy of breast cancer detection across both 2D and 3D mammography, particularly if you require advanced features like temporal comparison over several years and detailed breast density assessment. This tool is ideal for practices seeking to optimize radiologist workflow by providing region-based and overall exam scores, ultimately reducing workload for low-risk cases with its high negative predictive value.

View Transpara →

Choose ScreenPoint Medical if…

Choose ScreenPoint Medical (referring to their broader offerings including Transpara) if your institution is focused on a comprehensive AI solution for breast cancer detection and diagnosis that integrates seamlessly into existing PACS systems and offers enterprise-grade deployment options. This is suitable for large hospitals, clinics, and breast screening programs that prioritize regulatory clearances and require a robust AI assistant for both 2D and 3D mammography, including the prioritization of suspicious cases to streamline diagnostic pathways.

View ScreenPoint Medical →

When considering AI tools for breast imaging, physicians evaluating Transpara will find a robust solution designed to enhance breast cancer detection and optimize workflow for both 2D and 3D mammography. Transpara excels in providing AI-powered detection, temporal comparison against prior studies, and breast density assessment, offering both BI-RADS-like and volumetric insights. It also provides risk categorization and region-based/overall exam scores, making it suitable for practices prioritizing comprehensive AI assistance in diagnostic interpretation and workflow efficiency.

The key practical difference lies in the specific feature sets and how they cater to varying clinical needs. While both tools are from ScreenPoint Medical and offer core AI-powered breast cancer detection for 2D and 3D mammography, Transpara explicitly details advanced features like temporal comparison, breast density assessment, and risk categorization. These features are not explicitly listed for the more general “ScreenPoint Medical” tool description, suggesting Transpara is the product name encompassing these detailed functionalities. Therefore, a physician seeking a more granular AI assistant with capabilities like analyzing changes over time and detailed density assessment would likely opt for Transpara.

Ultimately, a physician should choose Transpara if their practice requires an AI solution with advanced analytical capabilities beyond basic detection, including temporal comparison, detailed breast density assessment, and risk stratification to support their diagnostic process and optimize workload. Practices primarily focused on general AI-powered detection and workflow prioritization for suspicious cases, without the need for the more granular features, might find the broader description of ScreenPoint Medical’s offerings sufficient, though it appears Transpara is the specific product delivering these capabilities.

Quick Comparison

Feature	Transpara	ScreenPoint Medical
Deployment	Transpara integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines. It is also available through Precision Imaging Network, part of Microsoft for Healthcare, which simplifies deployment pathways for cloud-enabled access within existing clinical ecosystems.	Cloud-enabled access through Precision Imaging Network (Microsoft for Healthcare), integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines, on-premise installations.
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both Tool A (Transpara) and Tool B (ScreenPoint Medical, which offers Transpara) describe integration into existing PACS and reading workflows via DICOM pipelines, and cloud-enabled access. This suggests a similar approach to usability and integration within a radiologist's existing environment. Without further specific details on UI/UX differences, it's difficult to declare a clear winner.

Clinical Value

Transpara

While both tools offer AI-powered breast cancer detection for 2D and 3D mammography, Tool A (Transpara) explicitly lists advanced features such as 'Temporal Comparison' (analyzing current study against up to 3 priors over 6 years), 'Breast Density assessment (BI-RADS-like and volumetric)', and 'Risk categorization (Elevated, Intermediate, Low)'. These additional features provide a more comprehensive clinical assessment beyond basic detection, offering greater clinical value. Tool A also highlights a 'High negative predictive value for low-risk cases (99.97%)' which is a strong indicator of clinical efficacy.

Pricing & Value

Tie

Neither the provided JSON nor general web searches offer specific pricing details for either Transpara or ScreenPoint Medical's offerings. Both are enterprise-level solutions, and pricing is likely customized based on deployment scale and features. Therefore, it's not possible to determine a winner in terms of pricing or value transparency.

Enterprise Readiness

Tie

Both Tool A (Transpara) and Tool B (ScreenPoint Medical) demonstrate strong enterprise readiness. They both integrate into existing PACS and reading workflows, offer cloud-enabled access, and have a significant global customer base (over 30 countries, over 13 million mammograms processed). Tool B specifically mentions being 'Selected by 40% of the 2025 US News and World Report's Top 20 Best Hospitals Honor Roll recipients,' further solidifying its enterprise adoption.

Innovation

Transpara

Tool A (Transpara) lists several innovative features that go beyond basic AI detection, such as 'Temporal Comparison' for analyzing prior studies, 'Breast Density assessment (BI-RADS-like and volumetric)', and 'Risk categorization'. These features demonstrate a more advanced application of AI to provide deeper insights and support for radiologists, indicating a higher degree of innovation compared to the more general feature list of Tool B.

Support & Docs

Tie

The provided information for both Tool A and Tool B does not include specific details regarding their support services or documentation. While both are established companies with significant deployments, there's no basis to differentiate their offerings in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Transpara	ScreenPoint Medical
Name	Transpara	ScreenPoint Medical
Description	Transpara is an FDA-cleared AI solution by ScreenPoint Medical B.V. that enhances breast cancer detection and optimizes radiologist workflow for 2D and 3D mammography.	ScreenPoint Medical offers Transpara, an AI-powered solution for breast cancer detection and diagnosis in mammography and digital breast tomosynthesis, designed to assist radiologists.
Company	ScreenPoint Medical	ScreenPoint Medical
API Available	yes	yes
Customer Count	Transpara is deployed in over 30 countries and has been used to analyze over 13 million mammograms worldwide. In 2025, it surpassed 11 million mammograms processed. As of September 2022, it had helped radiologists read over three million mammograms. In May 2023, over 4 million mammograms had been analyzed. It is used in over 200 clinics in 25+ countries.	Over 30 countries and 13 million mammograms processed. Over 200 healthcare facilities in more than 25 countries. Selected by 40% of the 2025 US News and World Report's Top 20 Best Hospitals Honor Roll recipients.
Headquarters	Nijmegen, Netherlands	Nijmegen, Netherlands
Founded Year	2014	2014
Key Features	AI-powered detection for 2D and 3D mammograms (FFDM and DBT), Temporal Comparison (analyzes current study against up to 3 priors over 6 years), Breast Density assessment (BI-RADS-like and volumetric), Risk categorization (Elevated, Intermediate, Low), Region-based and overall exam scores, Workflow optimization and workload reduction, Concurrent reading aid for radiologists, High negative predictive value for low-risk cases (99.97%)	AI-powered breast cancer detection, 2D mammography analysis, 3D digital breast tomosynthesis (DBT) analysis, Second-read assistance for radiologists, Prioritization of suspicious cases, Integration with PACS systems, Enterprise-grade deployment, Regulatory clearances (FDA, CE Mark, Health Canada, TGA)

Videos

Demos, reviews, and walkthroughs featuring Transpara and ScreenPoint Medical.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Transpara and ScreenPoint Medical's solutions integrate with existing EHR and PACS systems to fit into a radiologist's workflow?

Both Transpara and ScreenPoint Medical's solutions integrate into PACS and reading workflows via medical-imaging (DICOM) pipelines. Transpara is also available through the Precision Imaging Network, part of Microsoft for Healthcare, which simplifies deployment for cloud-enabled access within existing clinical ecosystems. ScreenPoint Medical also offers cloud-enabled access through the Precision Imaging Network and on-premise installations.

What is the accuracy and sensitivity of Transpara in detecting breast cancer in both 2D and 3D mammography?

Transpara offers AI-powered detection for both 2D and 3D mammograms (FFDM and DBT). It boasts a high negative predictive value of 99.97% for low-risk cases, aiming for earlier detection and enhanced workflow.

What is the typical learning curve for radiologists adopting Transpara, and what kind of support is available during implementation?

While specific details on the learning curve are not provided, Transpara is designed to optimize workflow and act as a concurrent reading aid, suggesting an intuitive design. ScreenPoint Medical, the company behind Transpara, has a significant global presence and customer base, implying established support structures for implementation and ongoing use.

Beyond standard security protocols, what advanced security features do Transpara and ScreenPoint Medical offer to protect patient data?

Both solutions integrate into PACS via DICOM pipelines, which inherently include security considerations for medical image transfer. While specific advanced security features beyond HIPAA are not detailed, their deployment through Microsoft for Healthcare's Precision Imaging Network suggests leveraging Microsoft's enterprise-grade security infrastructure. ScreenPoint Medical also mentions enterprise-grade deployment.

Can Transpara be effectively rolled out across multiple clinical sites, and what considerations should be made for such an implementation?

Transpara is deployed in over 30 countries and used in over 200 clinics, demonstrating its capability for multi-site rollouts. Its integration via DICOM pipelines and availability through cloud-enabled access (Precision Imaging Network) would facilitate standardized deployment and management across various locations.

What clinical context or specific features would help a physician choose between these two solutions for breast cancer detection?

Transpara offers temporal comparison (analyzing current studies against up to three prior studies over six years), breast density assessment (BI-RADS-like and volumetric), and risk categorization (Elevated, Intermediate, Low), along with region-based and overall exam scores. These features provide a more comprehensive clinical context for radiologists beyond basic detection.

What audit-trail features are available in Transpara to track AI assistance and radiologist interaction for diagnostic decisions?

While specific audit-trail features are not explicitly detailed, as an AI-powered detection and concurrent reading aid, it would be expected to log AI findings and radiologist interactions to support diagnostic decisions and provide a clear record for review.